<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01731691</url>
  </required_header>
  <id_info>
    <org_study_id>Prolastin-C in HIV disease</org_study_id>
    <nct_id>NCT01731691</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease</brief_title>
  <official_title>Safety and Efficacy of Prolastin®-C (α1Proteinase Inhibitor, α1PI) in Human Immunodeficiency Virus-Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Human Genetics and Biochemistry</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AIDS Community Research Initiative of America</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grifols Biologicals, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute for Human Genetics and Biochemistry</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our primary objective is to further characterize the mechanism by which alpha-1PI regulates&#xD;
      CD4 counts.&#xD;
&#xD;
      HIV-1 infected patients will be initiated on PROLASTIN®-C (Alpha-1 Proteinase Inhibitor&#xD;
      [Human], Grifols Biotherapeutics Inc.) or placebo. Uninfected volunteers will be untreated&#xD;
      and will be monitored for comparison.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study protocol is designed to investigate the benefit of a well-tolerated, FDA approved&#xD;
      biological product that has been extensively used in a different patient population.&#xD;
&#xD;
      For more than 20 years, α1proteinase inhibitor (α1PI or α1antitrypsin) therapy has been the&#xD;
      standard treatment for people with insufficient α1PI blood levels. This disorder, also known&#xD;
      as α1antitrypsin deficiency, was previously thought to be caused only as an inherited trait&#xD;
      due to the gene PIzz. Recent evidence shows that it can also be an acquired disease.&#xD;
      Specifically, individuals with HIV-1 disease have been found to have severely low α1PI blood&#xD;
      levels (Bristow et al., 2001; Bristow et al., 2010; Bristow et al., 2012). Many people with&#xD;
      the inherited version of α1PI deficiency eventually develop emphysema, and among individuals&#xD;
      with HIV-1 disease, 90% have acquired α1PI deficiency. Whether they go on to develop&#xD;
      emphysema is still unresolved.&#xD;
&#xD;
      HIV-1 infected individuals are the first patient population identified so far in which severe&#xD;
      α1PI deficiency is acquired through infection rather than being inherited.&#xD;
&#xD;
      It was found that a decrease in α1PI blood levels is directly correlated to a decrease in CD4&#xD;
      lymphocytes (Bristow et al., 2001; Bristow et al., 2012): In a pilot study to determine&#xD;
      whether α1PI therapy might benefit the CD4 counts in HIV-1 infected patients&#xD;
      (Clinicaltrials.gov NCT01370018), HIV-1 patients with infection-related α1PI deficiency&#xD;
      received weekly α1PI therapy (120mg/kg) for a period of 8 weeks and results were compared&#xD;
      with those of patients having the inherited version of α1PI deficiency who were&#xD;
      simultaneously receiving weekly α1PI therapy (60mg/kg). None of the patients in the study had&#xD;
      ever previously received α1PI therapy. It was found that CD4 cells rose to normal levels&#xD;
      following 2 weeks of intravenous α1PI therapy with no adverse effects observed in the HIV-1&#xD;
      patients (n=3) or the control group of HIV-1 uninfected, α1PI deficiency patients (n=2). The&#xD;
      new crop of CD4 cells were functional, capable of fighting infection, and appeared to be&#xD;
      generated from bone marrow-derived stem cells (Bristow et al., 2010). As a bonus, it was&#xD;
      found in the HIV-1 patients that LDL levels (bad cholesterol) decreased and HDL levels (good&#xD;
      cholesterol) increased {Bristow et al., in review).&#xD;
&#xD;
      The information gained from the initial pilot study will be incorporated into this study&#xD;
      design to further characterize the mechanism of lymphocyte renewal and to increase the number&#xD;
      of patients observed. Only minor modifications to the pilot protocol are proposed including&#xD;
      the sample size, addition of volunteers not receiving therapy, and a double-blind design: Ten&#xD;
      (10) HIV-1 infected patients will be dosed with PROLASTIN®-C (Grifols Therapeutics Inc.),&#xD;
      five (5) will be dosed with placebo, and five (5) uninfected volunteers not receiving therapy&#xD;
      will be monitored.&#xD;
&#xD;
      It has been observed that CD4 counts and cholesterol levels are correlated and that there is&#xD;
      cyclic variation in individuals with and without HIV. To examine whether there are&#xD;
      differences due to HIV infection in cyclic variation of CD4 counts, cholesterol levels, and&#xD;
      other values monitored during this study, five (5) volunteers, who do not have HIV, will be&#xD;
      included in the study for blood collection only.&#xD;
&#xD;
      In a previous study, we determined that in individuals with abnormally low active α1PI&#xD;
      levels, CD4 counts exhibit sinusoidal cycling with 23 day periodicity. Wave form appearance&#xD;
      of CD4 cells with a peak every 23 days is a pattern that is indicative of adult thymopoiesis.&#xD;
      We showed that in response to α1PI therapy, HIV infected and uninfected individuals exhibited&#xD;
      an increased CD4 counts axis of oscillation, but no change in periodicity. In contrast, one&#xD;
      uninfected individual who was not receiving therapy, exhibited no change in the axis of&#xD;
      oscillation, but periodicity was 27 days. Human adult thymopoiesis is not well characterized,&#xD;
      and based on these results, we have two hypotheses.&#xD;
&#xD;
      One hypothesis is that in response to α1PI therapy, thymopoiesis will increase, manifested by&#xD;
      an increased axis of oscillation and increased numbers of recent thymic emigrants. In the&#xD;
      proposed study, we will perform weekly TREC analysis which measures recent thymic emigrants&#xD;
      and is definitive for thymopoiesis. We will test whether the changes in TREC numbers&#xD;
      corresponds with changes in the CD4 counts axis of oscillation in HIV infected individuals&#xD;
      receiving α1PI therapy as compared with HIV infected individuals with abnormally low active&#xD;
      α1PI levels not on α1PI therapy, and HIV uninfected individuals with normal active α1PI&#xD;
      levels not on α1PI therapy.&#xD;
&#xD;
      The second hypothesis is that in individuals with abnormally low active α1PI levels, the&#xD;
      periodicity of CD4 counts is shorter than in individuals with normal active α1PI levels.&#xD;
      Although we will measure periodicity in only 5 individuals with normal active α1PI levels and&#xD;
      15 with abnormal active α1PI levels, this will allow us to determine whether active α1PI is a&#xD;
      linear determinate of periodicity or whether there are other variables that regulate&#xD;
      periodicity. In an 8-week study, only 2 periods can be observed. Thus, following an 8-week&#xD;
      regimen of therapy, one study subject may be asked to continue for a second 8-week regimen of&#xD;
      therapy to allow the observation of 5 periods.&#xD;
&#xD;
      In addition to these two primary hypotheses regarding CD4 counts, we have found that HDL and&#xD;
      LDL levels are linearly dependent on the balance of active and inactive α1PI levels&#xD;
      (manuscript in review). This phenomenon is due the transport of HDL and LDL by CD4 cells. We&#xD;
      found that in HIV infected individuals with abnormally low active α1PI and abnormally high&#xD;
      inactive α1PI, HDL and LDL increased or decreased differently from individuals with normal&#xD;
      active α1PI. Based on these results, our hypothesis is that in HIV infected individuals with&#xD;
      abnormally low active α1PI receiving α1PI therapy, LDL levels will decrease and HDL levels&#xD;
      will increase as active α1PI levels increase in contrast to HIV uninfected individuals with&#xD;
      normal active α1PI levels not on therapy and in contrast to HIV infected individuals with&#xD;
      abnormally low active α1PI levels not on therapy.&#xD;
&#xD;
      Prolastin-C treatment will be given weekly for eight (8) to sixteen (16) weeks by intravenous&#xD;
      infusion. Blood will be collected immediately prior to each infusion. As in the previous&#xD;
      study, complete blood count, lymphocyte phenotype, extended lymphocyte phenotype, lymphocyte&#xD;
      function; HIV-1 viral load, lipid levels, blood chemistry, and markers of inflammation will&#xD;
      be measured. The present study will also include measurements for HIV-1 tropism and markers&#xD;
      for recent thymic emigrants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Blinded review of the data suggested no significant diferences in outcomes.&#xD;
  </why_stopped>
  <start_date type="Actual">April 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD4 Counts</measure>
    <time_frame>9 weeks after initiation of treatment</time_frame>
    <description>It has been observed that CD4 counts and cholesterol levels are correlated and that there is cyclic variation in individuals with and without HIV.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD8</measure>
    <time_frame>9 weeks after initiation of treatment</time_frame>
    <description>It has been observed that CD4 counts and cholesterol levels are correlated and that there is cyclic variation in individuals with and without HIV.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4/CD8 Ratio</measure>
    <time_frame>9 weeks after initiation of treatment</time_frame>
    <description>It has been observed that CD4 counts and cholesterol levels are correlated and that there is cyclic variation in individuals with and without HIV.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alpha-1 Proteinase Inhibitor</measure>
    <time_frame>weekly for 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>sj/betaTrec Ratio</measure>
    <time_frame>weekly for 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>High Density Lipoprotein (HDL)</measure>
    <time_frame>weekly for 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Low Density Lipoprotein (LDL)</measure>
    <time_frame>weekly for 8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>HIV Disease</condition>
  <arm_group>
    <arm_group_label>α1 Proteinase Inhibitor in HIV disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>α1Proteinase Inhibitor (120mg/kg Prolastin-C) weekly for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in HIV disease</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebos weekly for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Uninfected controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Blood collection only for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>α1 Proteinase Inhibitor</intervention_name>
    <description>Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.</description>
    <arm_group_label>α1 Proteinase Inhibitor in HIV disease</arm_group_label>
    <other_name>Prolastin</other_name>
    <other_name>Prolastin-C</other_name>
    <other_name>Zemaira</other_name>
    <other_name>Glassia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo treatment in HIV disease will be compared with Prolastin-C treatment in HIV disease and no treatment in uninfected volunteers.</description>
    <arm_group_label>Placebo in HIV disease</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HIV-1 patients must have confirmed HIV-1 disease, diagnosed using the standard&#xD;
             criteria and be on antiretroviral therapy. Uninfected volunteers will be age and&#xD;
             gender matched.&#xD;
&#xD;
          2. HIV-1 patients must have measurable disease, defined as HIV-1 infected patients on&#xD;
             antiretroviral therapy with undetectable HIV RNA (&lt;1000 HIV RNA copies/ml) and CD4&#xD;
             counts more than 200 and less than 600 cells/uL.&#xD;
&#xD;
          3. Not have previously received α1PI augmentation therapy&#xD;
&#xD;
          4. Age at least 18 years and under 65 years&#xD;
&#xD;
          5. Capacity for and commitment to attend all protocol scheduled visits at ACRIA&#xD;
&#xD;
          6. Life expectancy of greater than 5 years&#xD;
&#xD;
          7. Patients must have lab values within the limits defined below:&#xD;
&#xD;
               -  WBC &gt;4,1000/uL&#xD;
&#xD;
               -  ANC &gt;1,000/uL&#xD;
&#xD;
               -  platelets &gt;100,000//uL&#xD;
&#xD;
               -  total bilirubin 2-12 mg/dL&#xD;
&#xD;
               -  AST(SGOT)/ALT(SGPT) &lt; or = 2.5 X upper limit of normal&#xD;
&#xD;
               -  creatinine Male : 0.50-1.30 mg/dL Female: 0.40-1.20 mg/dL&#xD;
&#xD;
          8. HIV-1 patients must have active α1PI below 11 uM (normal is 18-53 uM)&#xD;
&#xD;
          9. HIV-1 patients must have one year history (prior to the study) with CD4+ lymphocytes&#xD;
             at levels greater than 200 and less than 400 cells/uL&#xD;
&#xD;
         10. HIV-1 patients must have absence of symptoms suggestive of HIV-1 disease progression&#xD;
&#xD;
         11. HIV-1 patients must have adequate suppression of virus (&lt;400 HIV RNA/mL)&#xD;
&#xD;
         12. HIV-1 patients must have a history of compliance with antiretroviral medication based&#xD;
             on undetectable virus levels&#xD;
&#xD;
         13. No evidence of malignancy&#xD;
&#xD;
         14. The effects of Prolastin-C on the developing human fetus at the recommended&#xD;
             therapeutic dose are unknown: At any time throughout the study, from the signing of&#xD;
             the informed consent form until after the last study visit, all female and male&#xD;
             subjects who are biologically capable of having children must agree and commit to use&#xD;
             a reliable method of birth control.&#xD;
&#xD;
         15. Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recent illness that will prevent the patient from participating in required study&#xD;
             activities&#xD;
&#xD;
          2. Patients receiving other investigational agents&#xD;
&#xD;
          3. Patients with known malignancies&#xD;
&#xD;
          4. History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to Prolastin-C&#xD;
&#xD;
          5. IgA deficient patients&#xD;
&#xD;
          6. Patients with ≥1000 HIV-1 RNA copies/ mL&#xD;
&#xD;
          7. Patients with &gt;600 CD4 cells/uL&#xD;
&#xD;
          8. Uncontrolled illness including, but not limited to, ongoing or active infection,&#xD;
             myeloid dysplastic syndrome, anemia, bone marrow failure, DiGeorge Syndrome, thymic&#xD;
             disorders, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          9. Pregnant and breastfeeding women&#xD;
&#xD;
         10. Refusal to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Bristow, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Human Genetics and Biochemistry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ACRIA</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bristow CL, Babayeva MA, LaBrunda M, Mullen MP, Winston R. α1Proteinase inhibitor regulates CD4+ lymphocyte levels and is rate limiting in HIV-1 disease. PLoS One. 2012;7(2):e31383. doi: 10.1371/journal.pone.0031383. Epub 2012 Feb 17.</citation>
    <PMID>22363634</PMID>
  </reference>
  <reference>
    <citation>Bristow CL, Patel H, Arnold RR. Self antigen prognostic for human immunodeficiency virus disease progression. Clin Diagn Lab Immunol. 2001 Sep;8(5):937-42.</citation>
    <PMID>11527807</PMID>
  </reference>
  <results_reference>
    <citation>Bristow CL, Ferrando-Martinez S, Ruiz-Mateos E, Leal M, Winston R. Development of Immature CD4(+)CD8(+)T Cells Into Mature CD4(+) T Cells Requires Alpha-1 Antitrypsin as Observed by Treatment in HIV-1 Infected and Uninfected Controls. Front Cell Dev Biol. 2019 Nov 21;7:278. doi: 10.3389/fcell.2019.00278. eCollection 2019.</citation>
    <PMID>31824943</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 19, 2012</study_first_submitted>
  <study_first_submitted_qc>November 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2012</study_first_posted>
  <results_first_submitted>April 13, 2017</results_first_submitted>
  <results_first_submitted_qc>August 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 31, 2020</results_first_posted>
  <last_update_submitted>August 22, 2020</last_update_submitted>
  <last_update_submitted_qc>August 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Human Genetics and Biochemistry</investigator_affiliation>
    <investigator_full_name>Cynthia L Bristow, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Incomplete data was made available to the PI.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Volunteers were recruited by ACRIA by placing advertisements in neighborhood publications. A total of 227 patients were interviewed as potential candidates. The first study candidate was screened on January 14, 2013 and the first HIV+ subject was randomized (treatment/placebo) on April 25, 2013.</recruitment_details>
      <pre_assignment_details>Of the 21 potential subjects screened, 12 (57%) reached the baseline visit. All 12 were enrolled and all completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>α1 Proteinase Inhibitor in HIV Disease</title>
          <description>α1Proteinase Inhibitor (120mg/kg Prolastin-C) weekly for 8 weeks&#xD;
α1 Proteinase Inhibitor: Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.</description>
        </group>
        <group group_id="P2">
          <title>Placebo in HIV Disease</title>
          <description>Placebos weekly for 8 weeks&#xD;
Placebos: Placebo treatment in HIV disease will be compared with Prolastin-C treatment in HIV disease and no treatment in uninfected volunteers.</description>
        </group>
        <group group_id="P3">
          <title>Uninfected Controls</title>
          <description>Blood collection only for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>α1 Proteinase Inhibitor in HIV Disease</title>
          <description>α1Proteinase Inhibitor (120mg/kg Prolastin-C) weekly for 8 weeks&#xD;
α1 Proteinase Inhibitor: Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.&#xD;
The subjects in the HIV+ groups (Prolastin-C and Placebo) were not comparable to those in the HIV- group.</description>
        </group>
        <group group_id="B2">
          <title>Placebo in HIV Disease</title>
          <description>Placebos weekly for 8 weeks&#xD;
Placebos: Placebo treatment in HIV disease will be compared with Prolastin-C treatment in HIV disease and no treatment in uninfected volunteers.&#xD;
The subjects in the HIV+ groups (Prolastin-C and Placebo) were not comparable to those in the HIV- group.</description>
        </group>
        <group group_id="B3">
          <title>Uninfected Controls</title>
          <description>Blood collection only for 8 weeks&#xD;
The subjects in the HIV+ groups (Prolastin-C and Placebo) were not comparable to those in the HIV- group.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="5"/>
                    <measurement group_id="B2" value="52" spread="7"/>
                    <measurement group_id="B3" value="32" spread="10"/>
                    <measurement group_id="B4" value="46" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4</title>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="365" spread="116"/>
                    <measurement group_id="B2" value="438" spread="108"/>
                    <measurement group_id="B3" value="651" spread="239"/>
                    <measurement group_id="B4" value="491" spread="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD8</title>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="958" spread="340"/>
                    <measurement group_id="B2" value="872" spread="271"/>
                    <measurement group_id="B3" value="324" spread="53"/>
                    <measurement group_id="B4" value="711" spread="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4/CD8 Ratio</title>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.42" spread="0.17"/>
                    <measurement group_id="B2" value="0.53" spread="0.18"/>
                    <measurement group_id="B3" value="2.00" spread="0.58"/>
                    <measurement group_id="B4" value="0.99" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>α1 Proteinase Inhibitor</title>
          <description>Measured as active concentration, not as the traditional total concentration.</description>
          <units>uM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14" spread="4"/>
                    <measurement group_id="B2" value="12" spread="6"/>
                    <measurement group_id="B3" value="21" spread="10"/>
                    <measurement group_id="B4" value="15" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HDL</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="14"/>
                    <measurement group_id="B2" value="65" spread="14"/>
                    <measurement group_id="B3" value="58" spread="10"/>
                    <measurement group_id="B4" value="60" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89" spread="1.5"/>
                    <measurement group_id="B2" value="83" spread="16"/>
                    <measurement group_id="B3" value="83" spread="20"/>
                    <measurement group_id="B4" value="85" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CD4 Counts</title>
        <description>It has been observed that CD4 counts and cholesterol levels are correlated and that there is cyclic variation in individuals with and without HIV.</description>
        <time_frame>9 weeks after initiation of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>α1 Proteinase Inhibitor in HIV Disease</title>
            <description>α1Proteinase Inhibitor (120mg/kg Prolastin-C) weekly for 8 weeks&#xD;
α1 Proteinase Inhibitor: Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.&#xD;
The subjects in the HIV+ groups (Prolastin-C and Placebo) were not comparable to those in the HIV- group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in HIV Disease</title>
            <description>Placebos weekly for 8 weeks&#xD;
Placebos: Placebo treatment in HIV disease will be compared with Prolastin-C treatment in HIV disease and no treatment in uninfected volunteers.&#xD;
The subjects in the HIV+ groups (Prolastin-C and Placebo) were not comparable to those in the HIV- group.</description>
          </group>
          <group group_id="O3">
            <title>Uninfected Controls</title>
            <description>Blood collection only for 8 weeks&#xD;
The subjects in the HIV+ groups (Prolastin-C and Placebo) were not comparable to those in the HIV- group.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Counts</title>
          <description>It has been observed that CD4 counts and cholesterol levels are correlated and that there is cyclic variation in individuals with and without HIV.</description>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="326" spread="103"/>
                    <measurement group_id="O2" value="437" spread="180"/>
                    <measurement group_id="O3" value="649" spread="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD8</title>
        <description>It has been observed that CD4 counts and cholesterol levels are correlated and that there is cyclic variation in individuals with and without HIV.</description>
        <time_frame>9 weeks after initiation of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>α1 Proteinase Inhibitor in HIV Disease</title>
            <description>α1Proteinase Inhibitor (120mg/kg Prolastin-C) weekly for 8 weeks&#xD;
α1 Proteinase Inhibitor: Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in HIV Disease</title>
            <description>Placebos weekly for 8 weeks&#xD;
Placebos: Placebo treatment in HIV disease will be compared with Prolastin-C treatment in HIV disease and no treatment in uninfected volunteers.</description>
          </group>
          <group group_id="O3">
            <title>Uninfected Controls</title>
            <description>Blood collection only for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>CD8</title>
          <description>It has been observed that CD4 counts and cholesterol levels are correlated and that there is cyclic variation in individuals with and without HIV.</description>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="848" spread="202"/>
                    <measurement group_id="O2" value="946" spread="365"/>
                    <measurement group_id="O3" value="302" spread="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CD4/CD8 Ratio</title>
        <description>It has been observed that CD4 counts and cholesterol levels are correlated and that there is cyclic variation in individuals with and without HIV.</description>
        <time_frame>9 weeks after initiation of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>α1 Proteinase Inhibitor in HIV Disease</title>
            <description>α1Proteinase Inhibitor (120mg/kg Prolastin-C) weekly for 8 weeks&#xD;
α1 Proteinase Inhibitor: Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in HIV Disease</title>
            <description>Placebos weekly for 8 weeks&#xD;
Placebos: Placebo treatment in HIV disease will be compared with Prolastin-C treatment in HIV disease and no treatment in uninfected volunteers.</description>
          </group>
          <group group_id="O3">
            <title>Uninfected Controls</title>
            <description>Blood collection only for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>CD4/CD8 Ratio</title>
          <description>It has been observed that CD4 counts and cholesterol levels are correlated and that there is cyclic variation in individuals with and without HIV.</description>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.18"/>
                    <measurement group_id="O2" value="0.48" spread="0.14"/>
                    <measurement group_id="O3" value="2.20" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Alpha-1 Proteinase Inhibitor</title>
        <time_frame>weekly for 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>α1 Proteinase Inhibitor in HIV Disease</title>
            <description>α1Proteinase Inhibitor (120mg/kg Prolastin-C) weekly for 8 weeks&#xD;
α1 Proteinase Inhibitor: Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in HIV Disease</title>
            <description>Placebos weekly for 8 weeks&#xD;
Placebos: Placebo treatment in HIV disease will be compared with Prolastin-C treatment in HIV disease and no treatment in uninfected volunteers.</description>
          </group>
          <group group_id="O3">
            <title>Uninfected Controls</title>
            <description>Blood collection only for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Alpha-1 Proteinase Inhibitor</title>
          <units>micromol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="3.4"/>
                    <measurement group_id="O2" value="13.6" spread="4.1"/>
                    <measurement group_id="O3" value="19" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>sj/betaTrec Ratio</title>
        <time_frame>weekly for 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>α1 Proteinase Inhibitor in HIV Disease</title>
            <description>α1Proteinase Inhibitor (120mg/kg Prolastin-C) weekly for 8 weeks&#xD;
α1 Proteinase Inhibitor: Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in HIV Disease</title>
            <description>Placebos weekly for 8 weeks&#xD;
Placebos: Placebo treatment in HIV disease will be compared with Prolastin-C treatment in HIV disease and no treatment in uninfected volunteers.</description>
          </group>
          <group group_id="O3">
            <title>Uninfected Controls</title>
            <description>Blood collection only for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>sj/betaTrec Ratio</title>
          <units>sj/beta ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="353.52" spread="353.54"/>
                    <measurement group_id="O2" value="271.19" spread="414.34"/>
                    <measurement group_id="O3" value="375.96" spread="357.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>High Density Lipoprotein (HDL)</title>
        <time_frame>weekly for 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>α1 Proteinase Inhibitor in HIV Disease</title>
            <description>α1Proteinase Inhibitor (120mg/kg Prolastin-C) weekly for 8 weeks&#xD;
α1 Proteinase Inhibitor: Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in HIV Disease</title>
            <description>Placebos weekly for 8 weeks&#xD;
Placebos: Placebo treatment in HIV disease will be compared with Prolastin-C treatment in HIV disease and no treatment in uninfected volunteers.</description>
          </group>
          <group group_id="O3">
            <title>Uninfected Controls</title>
            <description>Blood collection only for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>High Density Lipoprotein (HDL)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.29" spread="6.21"/>
                    <measurement group_id="O2" value="63.14" spread="14.51"/>
                    <measurement group_id="O3" value="61.13" spread="10.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Low Density Lipoprotein (LDL)</title>
        <time_frame>weekly for 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>α1 Proteinase Inhibitor in HIV Disease</title>
            <description>α1Proteinase Inhibitor (120mg/kg Prolastin-C) weekly for 8 weeks&#xD;
α1 Proteinase Inhibitor: Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in HIV Disease</title>
            <description>Placebos weekly for 8 weeks&#xD;
Placebos: Placebo treatment in HIV disease will be compared with Prolastin-C treatment in HIV disease and no treatment in uninfected volunteers.</description>
          </group>
          <group group_id="O3">
            <title>Uninfected Controls</title>
            <description>Blood collection only for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Low Density Lipoprotein (LDL)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.67" spread="9.21"/>
                    <measurement group_id="O2" value="77.23" spread="25.19"/>
                    <measurement group_id="O3" value="75.19" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 weeks from initiation of therapy</time_frame>
      <desc>Zero patients experienced adverse events including in any of the following outcomes: death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Zero adverse events resulted in life-threatening incidents or hospitalization or jeopardized the participant.</desc>
      <group_list>
        <group group_id="E1">
          <title>α1 Proteinase Inhibitor in HIV Disease</title>
          <description>α1Proteinase Inhibitor (120mg/kg Prolastin-C) weekly for 8 weeks&#xD;
α1 Proteinase Inhibitor: Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.</description>
        </group>
        <group group_id="E2">
          <title>Placebo in HIV Disease</title>
          <description>Placebos weekly for 8 weeks&#xD;
Placebos: Placebo treatment in HIV disease will be compared with Prolastin-C treatment in HIV disease and no treatment in uninfected volunteers.</description>
        </group>
        <group group_id="E3">
          <title>Uninfected Controls</title>
          <description>Blood collection only for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed; Technical problems with measurement leading to unreliable or uninterpretable data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Cynthia L. Bristow</name_or_title>
      <organization>Institute for Human Genetics and Biochemistry</organization>
      <phone>631-444-6238</phone>
      <email>cynthia.bristow@stonybrook.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

